Other Body1 KnowCo's: Empower your Life™
Back1 Body1 Dental1 Diabetes1 Fibroids1 Heart1 Knee1 MedTech1 Reflux1 Shoulder1 Uterus1 Wounds1
Body1
 Register
 Login
 Main Page
 Vein News
Feature Story
Real Life Recoveries
 Education Center
Conditions
Procedures
Dr. Roger M. Greenhalgh  Veins
 Hero™

Dr. Roger M. Greenhalgh:
Vascular Surgeon and Patient Advocate.
About Heroes
 Join the Discussion in  Our Forums
 Community
Veins1 Forums
Patient Stories
 Reference
Ask an Expert
FAQ's
Locate a Doctor
Reference Library
Anatomy
Video Library
 Bookmark Us
advertisement
advertisement
Search the Body1 Network
   
December 01, 2008  
VEIN NEWS: Feature Story

  • Print this Article
  • Email this Article
  • Links/Reprints
  • Hemodialysis

    Developments in Vascular Access Systems for Hemodialysis Patients


    July 31, 2000

    By Janelle Mallett, Veins 1 Staff

    Patients with end-stage renal disease, due to irreparable kidney failure, must have their blood purified outside the body as much as three times a week. Biolink Corp, a medical device start-up in Middlebury, MA, raised $15.6 million in a private financing to advance the development of its vascular access system in the United States and to fuel the product's European introduction.

    Biolink's product, Dialock, is a vascular access tool designed to reduce common complications associated with hemodialysis. Vascular access products are used to access the blood easily, but conventional devices do not last long, have a high rate of infection, and blood clots, and limit blood flow. Some of these products also protrude from the neck or chest, an unappealing quality for many patients. Studies show that other products have also compromised the heart's function by increasing the cardio load.

    Biolink believes that its device can solve many of these problems. Its Dialock device consists of a titanium port, two catheters, and a liquid solution used between dialysis treatments. Surgeons implant the device beneath the skin in the upper chest area. It connects to the catheters between treatment to fight off thrombosis, blood clotting, and infection.

    Several sites in Europe, where most elements of the device are already approved, have reported a high rate of patient self-access with the devices, opening up the possibility for Dialock to compete in the home-based hemodialysis market. The company plans to complete the U.S. human clinical trials for Dialock later this year. Once these trials are complete, the company will apply for marketing approval with the Food and Drug Administration.

    The market for vascular access devices is $3 billion worldwide, including the money spent on access procedures and the repair and replacement of old devices. Frank Prosl, founded Biolink four years ago; he is also known for his innovations in chemotherapy access devices.

    Patients who will be starting hemodialysis treatments should work with their health-care team to learn how the treatments work. Consult your doctor about the different types of vascular access to ensure that the blood is easily and efficiently removed and replaced, while causing the least complications. For more information about vascular access for hemodialysis, visit:

    www.kidney.org


    References:

    Stringer, Judy. "Financing Gives Biolink Device Plans New Blood." Mass High Tech. Feb 14-20, 2000.

    www.biolink.com

    www.niddk.nih.gov

    Last updated: 31-Jul-00

    Comments

  • Add Comment
  •    
    Interact on Veins1

    Discuss this topic with others.
     
    Feature Archives

    2-Point DVT Diagnostic Tool Gets Approval

    Occasional Smokers Face Real Risks

    Thrombosis Strands Americans on Malta

    Screening For Abdominal Aortic Aneurysm

    Silver For Treating Wounds

    Next 5 Features ...

    More Features ...
       
     
    Related Multimedia

    Interview with Dr. Patel: How to Speed Recovery 1

     
    Related Content
    Researchers Tie Hard Arteries, Vein Clots

    Estrogen Patch Lowers Risk of Blood Clots

    DVT: Preventative Care Needed For At-Risk Patients

    Study: Leg Blood Clots Recur More in Men

    Anti-Clotting Drug Based on Bat Saliva

    More Features ...
     
    Home About Us Press Jobs Advertise With Us Contact Us
    advertisement
    ©1999- 2008 Body1, Inc. All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.
    See our Terms of Service, our Privacy Policy, our Advertising Policy and our Editorial Policy.